Characteristics of included studies
| Syphilis* (n=19) n (%) | Yaws* (n=7) n (%) | |
| POCTs | ||
| Chembio DPP-RDT | 15 (78.9) | 7 (100) |
| Smartphone dongle triplex test† | 1 (5.3) | 0 |
| SpanDiagnostics‡ | 1 (5.3) | 0 |
| Burnet TP-IgA | 2 (10.5) | 0 |
| Country income level§ | ||
| High | 9 (47.4) | 0 |
| Middle | 6 (31.6) | 6 (85.7) |
| Low | 2 (10.5) | 1 (14.3) |
| Mixed | 2 (10.5) | 0 |
| Study setting | ||
| General practice/clinic | 11 (57.9) | 1 (14.3) |
| Laboratory | 8 (42.1) | 0 |
| Field/non-clinical facility | 0 | 3 (42.9) |
| Unclear (includes unpublished data) | 0 | 3 (42.9) |
| Population | ||
| General population | 11 (57.9) | 3 (42.9) |
| Pregnant women | 4 (21.1) | 0 |
| MSM | 2 (10.5) | 0 |
| People living with HIV | 1 (5.3) | 0 |
| Children | 0 | 2 (28.6) |
| Other¶ | 1 (5.3) | 0 |
| Unclear (from unpublished data) | 0 | 2 (28.6) |
| Study design | ||
| Experimental/randomised controlled trial | 0 | 1 (14.3) |
| Observational/cross-sectional | 16 (84.2) | 2 (28.6) |
| Modelling | 2 (10.5) | 1 (14.3) |
| Qualitative | 1 (5.3) | 1 (14.3) |
| Unclear (from unpublished data) | 0 | 2 (28.9) |
| RDT reading method | ||
| Visual | 16 (84.2) | 6 (85.7) |
| Digital reader | 3 (15.8) | 1 (14.3) |
| Secondary outcomes | Total (n=15) | |
| Acceptability | 2 (13) | |
| Feasibility | 2 (13) | |
| Usability | 5 (33) | |
| Appropriate treatment following testing | 4 (27) | |
| Cost/resources | 2 (13) |
*The total of studies for each category does not add up to 25 as one paper contained data for both syphilis and yaws.
†HIV, treponemal and non-treponemal RDT, not commercially available.
‡Similar to DPP-RDT, manufactured by Span Diagnostics.
§Country income level is classified as per the World Bank Group.
¶(>15 years old+behavioural risk group): (1) injection drug users (IDUs) with verified track marks (eg, visible signs of injection); (2) women who reported at least two male partners in the last 2 years or engaging in anal intercourse, sex trading, or sex with an MSM, an IDU, or an HIV-positive man; (3) MSM and men who have sex with men and women; and (4) transgender individuals.
DPP, Dual Path Platform; MSM, men who have sex with men; POCTs, point-of-care tests; RDT, rapid diagnostic test; TP-IgA, treponemal IgA-specific assay.